Loading...

Financial Summary


Ablynx NV

Ablynx NV (ABLX)

Healthcare
-
-
Market Info
Financial Info
Financial Modelling
Symbol ABLX
Price 52.78$
Beta 8.24
Volume Avrg. 0.13M
Market Cap 3.27B
Shares (2017) 62,000.00K
Last Div 0
Dividend Yield -
DCF Unlevered 2.40 Strong Sell
DCF Levered 3.51 Strong Sell
ROE NaN%
ROA NaN%
Operating Margin -96.43% Strong Sell
Debt / Equity NaN%
P/E -
P/B -

Income Statement

Download ABLX income statement Download ABLX income statement
Year 20132014201520162017
Revenue 33.0048.0077.0085.0056.00
Cost of Revenue 44.0054.0083.00100.0091.00
Gross Profit -11.00-7.00-6.00-16.00-35.00
R&D Expenses -----
Sales, General and Administrative Expense 8.009.009.0011.0016.00
Operating Expenses 7.009.0011.0013.0019.00
Operating Income -18.00-16.00-17.00-29.00-54.00
Interest Expense --4.007.007.00
Earnings before Tax -19.00-13.00-55.00-1.00-109.00
Income Tax Expense -----
Net Income -19.00-13.00-55.00-1.00-109.00
Net Income - Non-Controlling int -----
Net Income - Discounted ops -----
Net Income Com -19.00-13.00-55.00-1.00-109.00
Preferred Dividends -----
Earnings Per Share Basic -0.41-0.25-1.00-0.02-1.74
Earnings Per Share Diluted -0.41-0.25-1.00-0.02-1.74
Weighted Average Shares Outstanding 48.0051.0054.0058.0062.00
Weighted Average Shares Outstanding (Diluted) 48.0051.0054.0058.0062.00
Dividend per Share -----
Gross Margin -0.33-0.15-0.08-0.19-0.63
EBITDA Margin -0.52-0.23-0.640.09-1.75
EBIT Margin -0.58-0.27-0.660.07-1.82
Profit Margin -0.58-0.27-0.71-0.01-1.95
Free Cash Flow margin -----
EBITDA -17.00-11.00-49.008.00-98.00
EBIT -19.00-13.00-51.006.00-102.00
Consolidated Income -19.00-13.00-55.00-1.00-109.00
Earnings Before Tax Margin -0.58-0.27-0.71-0.01-1.95
Net Profit Margin -0.58-0.27-0.71-0.01-1.95

Balance Sheet Statement

Download ABLX income statement Download ABLX income statement
Year 20132014201520162017
Cash and cash equivalents 11.0012.004.0053.0015.00
Short-term investments 188.00193.00231.00180.00288.00
Cash and short-term investments 188.00193.00231.00180.00288.00
Receivables --7.004.002.00
Inventories -----
Property, Plant & Equipment Net 2.002.003.004.004.00
Goodwill and Intangible Assets ---2.001.00
Long-term investments ----50.00
Tax assets -----
Total non-current assets --135.00104.00166.00
Total current assets 13.0017.0019.0025.0079.00
Total assets 214.00223.00265.00267.00390.00
Payables 5.003.004.006.005.00
Short-term debt -----
Total current liabilities 167.00148.00103.0059.0044.00
Long-term debt --135.00104.0089.00
Total debt --135.00104.0089.00
Deferred revenue ----11.00
Tax Liabilities -----
Deposit Liabilities -----
Total non-current liabilities --135.00104.00166.00
Total liabilities 167.00148.00237.00164.00210.00
Other comprehensive income -----
Retained earnings (deficit) -195.00-208.00-262.00-263.00-372.00
Total shareholders equity 46.0075.0028.00103.00180.00
Investments ----50.00
Net Debt -11.00-12.00131.0051.0074.00
Other Assets 12.0017.0021.0024.0030.00
Other Liabilities -1.001.001.0073.00

Cash Flow Statement

Download ABLX income statement Download ABLX income statement
Year 20132014201520162017
Depreciation & Amortization 2.002.001.002.003.00
Stock-based compensation 1.002.002.003.003.00
Operating Cash Flow 106.00-32.00-69.00-67.00-58.00
Capital Expenditure -1.00-2.00-2.00-5.00-3.00
Acquisitions and disposals ----2.00-
Investment purchases and sales -131.00-5.00-38.0051.00-158.00
Investing Cash Flow -----
Insurance (repayment) of debt -----
Insurance (buybacks) of shares -----
Dividend payments -----
Financing Cash Flow 32.0040.00101.0070.00179.00
Effect of forex changes on cash -----
Net cash flow / Change in cash 6.001.00-8.0050.00-38.00
Free Cash Flow 105.00-34.00-71.00-71.00-61.00
Net Cash/Marketcap -----

Retained Earning Schedule

Year 20132014201520162017
Retained Earnings (Previous Year) --195-208-262-263
Net Income -19-13-55-1-109
Stock Dividends -176-1--
Divident Paid -----
Retained Earnings -195-208-262-263-372
Year 20132014201520162017
Gross PPE -2234
Annual Depreciation 32363
Capital Expenditure -1-2-2-5-3
Net PPE 22344

Intangible and Goodwill Schedule

Year 20132014201520162017
Intangible and Goodwill (Previous Year) ----2
New Purchases -131-5-3851-158
Intangible and Goodwill ---21
Ablynx NV

Ablynx NV (ABLX)

52.78
0 (0.00%)

About


Edwin Moses
Healthcare
Biotechnology
Nasdaq Global Select

Ablynx NV is a clinical-stage biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments.